Company press releases and official corporate announcements.
A centralized feed of corporate press releases, earnings announcements, mergers, and official statements. Content is presented for informational purposes and may require additional analysis for market relevance.
10,073 total articles
Aduro Clean Technologies has appointed Jan Lemmens as Project Director to lead the engineering, permitting, and construction preparation of its first-of-a-kind Hydrochemolytic™ chemical recycling facility at Chemelot Industrial Park, Netherlands. The facility, aimed at processing 10,000 tonnes of waste plastics annually, is a strategic initiative t…
Rent the Runway, Inc. announced its Q1 fiscal 2026 results, achieving $89.9 million in revenue, up 29.2% year-over-year, exceeding guidance. The company showed improvement in EBITDA margin and add-on revenue increased by 70.4% YoY. New interim leadership appointments were made, and the company highlighted AI-driven personalization enhancements to i…
Powerus and Swarmer have signed a Memorandum of Understanding to explore integration of Swarmer's vendor-agnostic autonomous swarming software with Powerus's air and maritime autonomous systems. The collaboration targets defense, counter-drone, border security, and critical infrastructure protection missions. The MOU focuses on technical evaluation…
Medicus Pharma announces the submission of Protocol SKNJCT-005 to the FDA for a Phase 2b open-label registrational study of SkinJect® in patients with Gorlin Syndrome, a rare genetic disorder characterized by multiple basal cell carcinomas. The study aims to generate efficacy and safety data supporting a future New Drug Application (NDA) for SkinJe…
Celularity Inc., a US-based regenerative and cellular medicine company, announced the appointment of Rick Gonzalez as Chief Commercial Officer. Gonzalez brings extensive leadership experience in biotechnology and healthcare commercialization, supporting Celularity's efforts to advance its placental-derived cellular therapies, including cenplacel-L …
VenHub Global, Inc. announced its support of the Culver City GoPass program, which has enabled over 56,000 free transit trips for K-12 students, benefiting nearly 600 active riders and saving families approximately $100,000 in transportation costs. The initiative aligns with VenHub's mission to connect communities by deploying autonomous Smart Stor…
Biogen announced presentations of 14 abstracts highlighting clinical data from its nephrology portfolio, including approved drug EMPAVELI (pegcetacoplan) and the investigational anti-CD38 antibody felzartamab, at the European Renal Association and American Transplant Congresses. The data show sustained efficacy and safety in treating rare kidney di…
Bread Financial Holdings announced its participation in the upcoming Morgan Stanley US Financials Conference, where CFO Perry Beberman will engage in a fireside chat. The company is showcasing its tech-forward financial services and payment solutions targeting millions of U.S. consumers, highlighting its 30 years of industry presence.
Dyne Therapeutics has completed enrollment of 71 participants in the registrational expansion cohort of its Phase 1/2 ACHIEVE trial evaluating z-basivarsen (DYNE-101) for treatment of myotonic dystrophy type 1 (DM1). Topline data are anticipated in Q1 2027, supporting a potential U.S. Accelerated Approval submission by Q3 2027 and possible launch i…
TG Therapeutics announced favorable Phase 1 trial results for their high-concentration subcutaneous formulation of BRIUMVI (ublituximab-xiiy), showing good tolerability, sustained drug exposure, and comparable biological activity versus intravenous administration. The data bolster confidence in the ongoing Phase 3 trial evaluating quarterly subcuta…
Palvella Therapeutics has completed a pre-New Drug Application meeting with the FDA for its investigational drug QTORIN™ rapamycin, aimed at treating microcystic lymphatic malformations, a serious and chronic vascular malformation with no current FDA-approved treatment. The company remains on track to submit its NDA in the second half of 2026 and p…
Celcuity Inc., a clinical-stage biotechnology company focused on targeted therapies for solid tumors, announced a proposed underwritten public offering of $400 million in convertible senior notes due 2032, with an option to increase by $60 million for over-allotments. Net proceeds will be used primarily to repay existing debt and for working capita…
GigaCloud Technology Inc, listed on Nasdaq as GCT, announced its inclusion in TIME's 'World’s Growth Leaders 2026' list, highlighting its strong multi-year revenue growth, financial stability, and market performance. The company is noted for its innovative B2B ecommerce platform that integrates technology, fulfillment, and marketplace ecosystems to…
Destination XL Group, Inc. announced that its board is reevaluating the previously announced merger with FullBeauty Brands due to a more challenging consumer environment and FullBeauty's indebtedness, considering the existing merger terms not in the best interests of DXL stockholders. The company remains committed to maximizing shareholder value an…
IREN Limited revealed plans for an 800MW data center campus in Bundey, South Australia, secured by a new high-voltage transmission connection. The project, set to begin energization by 2028, aims to support the rapidly growing AI infrastructure demand across the Asia-Pacific region. The campus leverages South Australia's target of 100% renewable en…
GXO Logistics has appointed Roberto Pascual as Managing Director for Spain and Portugal, aiming to intensify customer-centricity, accelerate vertical growth, and deploy advanced automation. Pascual brings over 25 years of contract logistics experience, previously serving as Managing Director at DHL Supply Chain Iberia. This leadership change follow…
FactSet announced that it will release its Q3 fiscal 2026 financial results on July 1, 2026, and will host a conference call to discuss the results along with a Q&A session. The company provides advanced financial data and analytics solutions to various sectors globally.
ScottsMiracle-Gro reaffirmed its fiscal 2026 financial guidance, citing approximately 1 percent growth in branded consumer point-of-sale dollars year-to-date and securing 90% of commodity costs to mitigate inflation. The company projects low single-digit U.S. consumer net sales growth, a gross margin of at least 32%, adjusted EBITDA growth, and fre…
SweetWater Brewing, the Southeast's leading craft beer brand and subsidiary of Tilray Brands (NASDAQ: TLRY), announced a citywide soccer celebration in Atlanta for summer 2026. Leveraging Atlanta hosting major international soccer matches, the program includes stadium activations, fan experiences, exclusive beer collaborations, and watch parties to…
FibroBiologics has dosed the first patients in its Phase 1/2 clinical trial of CYWC628, a topical allogeneic fibroblast-spheroid cell therapy designed to treat diabetic foot ulcers (DFUs). The multicenter, randomized study in Australia aims to evaluate safety, tolerability, and efficacy by comparing CYWC628 plus standard of care (SoC) against SoC a…
Axsome Therapeutics announced a settlement resolving all patent litigation related to its CNS disorder treatment SUNOSI (solriamfetol), allowing generic versions to enter the US market only after 2040 under specified conditions. This agreement removes ongoing legal uncertainties and reinforces Axsome's market exclusivity for SUNOSI in the US for ma…
Upstream Bio, a clinical-stage biopharmaceutical company focused on treatments for inflammatory and severe respiratory diseases, announced CEO Dr. Rand Sutherland will participate in a fireside chat at the Goldman Sachs 47th Annual Global Healthcare Conference on June 10, 2026. The company is currently advancing its lead candidate, verekitug, a mon…
Avalyn Pharma reported Q1 2026 financial results and key updates, highlighting progress in its inhaled therapy clinical trials for pulmonary fibrosis, including ongoing enrollment in its MIST Phase 2b and AURA Phase 2 trials and plans to initiate a Phase 1 trial for a combination therapy. The company successfully raised $345 million in an upsized I…
Cabaletta Bio announced encouraging clinical data for its investigational autologous CAR T cell therapy, rese-cel, showing durable, immunomodulator-free responses in patients with autoimmune diseases including dermatomyositis, systemic sclerosis, and lupus. The data support advancement in registrational studies and highlight potential for precondit…
Ovid Therapeutics Inc. has appointed Dr. Anna Greka, a distinguished physician-scientist and biotech innovator, to its Board of Directors. Dr. Greka will chair Ovid's new Science and Technology Committee and contribute to advancing Ovid's pipeline of targeted therapies for neurological and neuropsychiatric disorders, including epilepsy and KCC2 act…
